TITLE

Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenolype-low (CIMP-low) in colorectal cancer

AUTHOR(S)
Ogino, Shuji; Kawasaki, Takako; Kirkner, Gregory J.; Suemoto, Yuko; Meyerhardt, Jeffrey A.; Fuchs, Charles S.
PUB. DATE
November 2007
SOURCE
Gut;Nov2007, Vol. 56 Issue 11, p1564
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The CpG island methylator phenotype (CIMP or CIMP-high) with widespread promoter methylation is a distinct epigenetic phenotype in colorectal cancer. In contrast, a phenotype with less widespread promoter methylation (CIMP-low) has not been well characterised. O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and silencing have been associated with G>A mutations and microsatellite instability-low (MSI-low). Aim: To examine molecular correlates with MGMT methylation/silencing in colorectal cancer. Methods: Utilising MethyLight technology, we quantified DNA methylation in MGMT and eight other markers (a CIMP-diagnostic panel; CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) in 920 population-based colorectal cancers. Results: Tumours with both MGMT methylation and loss were correlated positively with MSI-low (p=0.02), CIMP-high (⩾6/8 methylated CIMP markers, p=0.005), CIMP-low (1/8-5/8 methylated CIMP markers, p = 0.002, compared to CIMP-O with 0/8 methylated markers), KRAS G>A mutation (p = 0.02), and inversely with 18q loss of heterozygosity (p = 0.0002). Tumours were classified into nine MSI/CIMP subtypes. Among the CIMP-low group, tumours with both MGMT methylation and loss were far more frequent in MSI-low tumours (67%, 12/18) than MSI-high tumours (5.6%, 1/18; p=0.0003) and microsatellite stable (MSS) tumours (33%, 52/160; p=0.008). However, no such relationship was observed among the CIMP-high or CIMP-0 groups. Conclusion: The relationship between MGMT methylation/silencing and MSI-low is limited to only CIMP-low tumours, supporting the suggestion that CIMP-low in colorectal cancer may be a different molecular phenotype from CIMP-high and CIMP-0. Our data support a molecular difference between MSI-low and MSS in colorectal cancer, and a possible link between CIMP-low, MSI-low, MGMT methylation/loss and KRAS mutation.
ACCESSION #
27560504

 

Related Articles

  • CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Ogino, S.; Cantor, M.; Kawasaki, I.; Brahmandam, M.; Kirkner, G. J.; Weisenberger, D. J.; Campan, M.; Laird, P. W.; Loda, M.; Fuchs, C. S. // Gut;Jul2006, Vol. 55 Issue 7, p1000 

    Background: The concept of CpG island methylator phenotype (CIMP) is not universally accepted. Even if specific clinicopathological features have been associated with CIMP, investigators often failed to demonstrate a bimodal distribution of the number of methylated markers, which would suggest...

  • CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Ting, Angela H.; Kam-Wing Jair; Suzuki, Hiromu; Ray-Whay Chiu Yen; Baylin, Stephen B.; Schuebel, Kornel E. // Nature Genetics;Jun2004, Vol. 36 Issue 6, p582 

    The role of the primary mammalian DNA methyltransferase, DNMT1, in maintaining CpG island methylation in human colon cancer cells has recently been questioned. This controversy has arisen from discrepancies between genetic knockout and RNA interference-mediated knockdown studies. Here, we...

  • EPIGENETICS.  // Nature Reviews Cancer;Oct2003, Vol. 3 Issue 10, p719 

    The article discusses genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. It is found that tumour-suppressor genes are often silenced in tumours by hypermethylation of the CpG islands within the genes. It was also found...

  • TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Fariña-Sarasqueta, A.; Gosens, M.; Moerland, E.; Lijnschoten, I.; Lemmens, V.; Slooter, G.; Rutten, H.; Brule, Adriaan // Cellular Oncology (2211-3428);Aug2011, Vol. 34 Issue 4, p327 

    Aim: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. With this study, we aimed to elucidate the role of TS gene...

  • Hereditary non-polyposis colorectal cancer is predicted to contribute towards colorectal cancer in young South African blacks. Cronjé, L.; Becker, P. J.; Paterson, A. C.; Ramsay, M. // South African Journal of Science;Jan/Feb2009, Vol. 105 Issue 1/2, p68 

    A disproportionately large number of young (<50 years) black patients present with colorectal cancer (CRC) in South Africa. Although a phenomenon previously described elsewhere in Africa, its specific molecular basis, whether sporadic or hereditary, has not been established. Molecular analysis...

  • Epigenetics: Dissecting driving DNA methylations. Burgess, Darren J. // Nature Reviews Cancer;Jul2012, Vol. 12 Issue 7, p448 

    The article presents the study of Peter Jones and colleagues that investigates the putative methylation of driver gene on where cancer cells rely. Researchers did a comparison between parent and daughter clones of HCT116 colorectal cancer cells. They found that daughter cells engineered the DNA...

  • CpG methylation is maintained in human cancer cells lacking DNMT1. Rhee, Ina; Jair, Kam-Wing // Nature;4/27/2000, Vol. 404 Issue 6781, p1003 

    Tests that hypothesis that the prototypic DNA methyltransferase, DNMT1, is responsible for most of the methylation of the human genome, including the abnormal methylation found in cancers. Disruption of the DNMT1 gene through homologous recombination in human colorectal carcinoma cells; Results.

  • Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Shuji Ogino // Gut;Mar2011, Vol. 60 Issue 3, p397 

    Colorectal cancer is a complex disease resulting from somatic genetic and epigenetic alterations, including locus-specific CpG island methylation and global DNA or LINE-1 hypomethylation. Global molecular characteristics such as microsatellite instability (MSI), CpG island methylator phenotype...

  • Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors. Sakamoto, Naoto; Terai, Takeshi; Ajioka, Yoichi; Abe, Satoshi; Kobayasi, Osamu; Hirai, Shu; Hino, Okio; Watanabe, Hidenobu; Sato, Nobuhiro; Shimoda, Tadakazu; Fujii, Hiroaki // Oncogene;11/25/2004, Vol. 23 Issue 55, p8900 

    Flat colorectal tumors, characterized by high-grade dysplasia from early small flat mucosal lesions, exhibit a relatively aggressive clinical behavior and are known for their infrequent K-ras mutations. In this study, we investigated the methylation status of the RASSF1A promoter in association...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics